A Possible Inhibitory Role of Sialic Acid on MUC1 in Peritoneal Dissemination of Clear Cell-Type Ovarian Cancer Cells
- PMID: 34641504
- PMCID: PMC8512441
- DOI: 10.3390/molecules26195962
A Possible Inhibitory Role of Sialic Acid on MUC1 in Peritoneal Dissemination of Clear Cell-Type Ovarian Cancer Cells
Abstract
The role of sialic acids on MUC1 in peritoneal dissemination of ovarian cancer cells was investigated. A human ovarian carcinoma cell line, ES-2, was transfected with full-length MUC1 containing 22 or 42 tandem repeats. These transfectants were less adherent to monolayers of patient-derived mesothelial cells than ES-2/mock transfectants. When these cells were inoculated into the abdominal cavity of female nude mice, mice that had received the transfectants showed better survival. When the transfectants were mixed with sialidase and injected, the survival was poorer, whereas when they were mixed with N-acetyl-2,3-dehydro-2-deoxyneuraminic acid, a sialidase inhibitor, the survival was significantly prolonged. These behaviors, concerned with peritoneal implantation and dissemination observed in vitro and in vivo, were dependent on the expression of MUC1. Therefore, sialic acid linked to MUC1 in the form, at least in part, of sialyl-T, as shown to be recognized by monoclonal antibody MY.1E12, is responsible for the suppression of adhesion of these cells to mesothelial cells and the suppression of peritoneal implantation and dissemination.
Keywords: mucins; neuraminidase; ovarian neoplasms; peritoneal dissemination; sialic acid.
Conflict of interest statement
The authors declare no conflict of interest. The sponsors had no role in the design, execution, interpretation, or writing of the study.
Figures





Similar articles
-
A novel monoclonal antibody specific for sialylated MUC1 mucin.Jpn J Cancer Res. 1996 May;87(5):488-96. doi: 10.1111/j.1349-7006.1996.tb00250.x. Jpn J Cancer Res. 1996. PMID: 8641986 Free PMC article.
-
The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat.J Immunol Methods. 2002 Dec 15;270(2):199-209. doi: 10.1016/s0022-1759(02)00298-3. J Immunol Methods. 2002. PMID: 12379325
-
Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin.Tumour Biol. 1998;19 Suppl 1:100-10. doi: 10.1159/000056510. Tumour Biol. 1998. PMID: 9422094
-
The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.Cancer Metastasis Rev. 2013 Dec;32(3-4):535-51. doi: 10.1007/s10555-013-9423-y. Cancer Metastasis Rev. 2013. PMID: 23609751 Review.
-
Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.Immunol Res. 2013 Dec;57(1-3):70-80. doi: 10.1007/s12026-013-8451-6. Immunol Res. 2013. PMID: 24222275 Review.
Cited by
-
Aberrant Sialylation in Ovarian Cancer: Orchestrating Progression, Metastasis, and Therapeutic Hurdles.Curr Med Sci. 2025 Jun;45(3):395-404. doi: 10.1007/s11596-025-00041-3. Epub 2025 Apr 17. Curr Med Sci. 2025. PMID: 40244513 Review.
-
Study on the Construction and Anti-Tumor Effect of aPDL1/aMUC1 Double Antibody Modification of Doxorubicin Liposome.ACS Omega. 2025 Mar 3;10(10):10107-10121. doi: 10.1021/acsomega.4c08564. eCollection 2025 Mar 18. ACS Omega. 2025. PMID: 40124041 Free PMC article.
-
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.Cancer Biol Med. 2023 May 3;20(5):369-84. doi: 10.20892/j.issn.2095-3941.2023.0046. Cancer Biol Med. 2023. PMID: 37133224 Free PMC article. Review.
-
Unique Glycoform-Dependent Monoclonal Antibodies for Mouse Mucin 21.Int J Mol Sci. 2022 Jun 16;23(12):6718. doi: 10.3390/ijms23126718. Int J Mol Sci. 2022. PMID: 35743163 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous